[HTML][HTML] Dopamine, immunity, and disease

B Channer, SM Matt, EA Nickoloff-Bybel, V Pappa… - Pharmacological …, 2023 - Elsevier
The neurotransmitter dopamine is a key factor in central nervous system (CNS) function,
regulating many processes including reward, movement, and cognition. Dopamine also …

Vitiligo: a review

C Bergqvist, K Ezzedine - Dermatology, 2020 - karger.com
Vitiligo, a common depigmenting skin disorder, has an estimated prevalence of 0.5–2% of
the population worldwide. The disease is characterized by the selective loss of melanocytes …

The role of oxidative stress in vitiligo: an update on its pathogenesis and therapeutic implications

WL Chang, CH Ko - Cells, 2023 - mdpi.com
Vitiligo is an autoimmune skin disorder caused by dysfunctional pigment-producing
melanocytes which are attacked by immune cells. Oxidative stress is considered to play a …

Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach

A Cuadrado, G Manda, A Hassan, MJ Alcaraz… - Pharmacological …, 2018 - Elsevier
Abstract Systems medicine has a mechanism-based rather than a symptom-or organ-based
approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In …

Mechanisms of melanocyte death in vitiligo

J Chen, S Li, C Li - Medicinal Research Reviews, 2021 - Wiley Online Library
Vitiligo is an autoimmune depigment disease results from extensive melanocytes
destruction. The destruction of melanocyte is thought to be of multifactorial causation …

Vitiligo: a focus on pathogenesis and its therapeutic implications

C Bergqvist, K Ezzedine - The Journal of dermatology, 2021 - Wiley Online Library
Vitiligo is the most common depigmenting disorder affecting 0.1%–2% of the population
worldwide. The characteristic white patches result from the selective loss of melanocytes …

The role of oxidative stress in the pathogenesis of vitiligo: a culprit for melanocyte death

Y Xuan, Y Yang, L **ang… - Oxidative medicine and …, 2022 - Wiley Online Library
Vitiligo is a common chronic acquired pigmentation disorder characterized by loss of
pigmentation. Among various hypotheses proposed for the pathogenesis of vitiligo, oxidative …

Vitiligo, from pathogenesis to therapeutic advances: state of the art

F Diotallevi, H Gioacchini, E De Simoni… - International Journal of …, 2023 - mdpi.com
Vitiligo is an acquired hypopigmentation of the skin due to a progressive selective loss of
melanocytes; it has a prevalence of 1–2% and appears as rounded, well-demarcated white …

Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy

K Boniface, J Seneschal, M Picardo, A Taïeb - Clinical reviews in allergy & …, 2018 - Springer
Vitiligo is an acquired chronic depigmenting disorder of the skin, with an estimated
prevalence of 0.5% of the general population, characterized by the development of white …

T cell pathology in skin inflammation

R Sabat, K Wolk, L Loyal, WD Döcke… - Seminars in …, 2019 - Springer
Forming the outer body barrier, our skin is permanently exposed to pathogens and
environmental hazards. Therefore, skin diseases are among the most common disorders. In …